Thyroid carcinoma

Current Opinion in Oncology

Volumn 18, Issue 1, 2006, Pages 30-35

  Weber, Theresia ^a,b   Schilling, Tobias ^a   Büchler, Markus W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Department of Surgery ^*  (Germany)

Author keywords

Differentiated thyroid carcinoma; Medullary thyroid carcinoma; Prognostic factors; Surgical therapy; Survival rates

Indexed keywords

CALCITONIN;

CERVICAL LYMPH NODE; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; ECHOGRAPHY; HUMAN; PRIORITY JOURNAL; RECURRENT LARYNGEAL NERVE; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROIDECTOMY;

BIOLOGICAL MARKERS; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY, FOLLICULAR; HUMANS; PROGNOSIS; SURVIVAL RATE; THYROID NEOPLASMS; THYROIDECTOMY; VOCAL CORD PARALYSIS;

EID: 33646675549     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000198975.36368.d3     Document Type: Review

References (35)

1. Ries LAG, Eisner MP, Kosary CL, et al. editors. SEER Cancer Statistics Review, 1975-1992. Bethesda, MD: National Cancer Institute. http://seer.cancer. go/cgi-bin/CST/1975-2002/search.pl#results as posted on the SEER website 2005.
2. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003; 134:946-955.
3. Ito Y, Tomoda C, Uruno T, et al. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg 2005 [Epub ahead of print].
4. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10, 864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89:163-168. Excellent data on measurement of calcitonin levels before surgery in patients with thyroid nodules and consequences for surgical treatment.
5. Gibelin H, Essique D, Jones C, et al. Increased calcitonin levels in thyroid nodules without medullary carcinoma. Br J Surg 2005; 92:574-578. Data on use of serum calcitonin before surgery in patients with thyroid nodules.
6. Machens A, Schneyer U, Holzhausen H-J, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005; 90:2029-2034. Excellent study on the influence of calcitonin levels on the outcome of surgical treatment in medullary thyroid carcinoma.
7. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104:947-953.
8. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114:1050-1057.
9. Kim S, Braveman JM, Brams DM. Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg 2004; 139:390-394. Study displaying improved survival rates for patients older than 60 years with PTC treated with total thyroidectomy compared with lobectomy.
10. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol 2005; 12:81-89.
11. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocrine Practice 2001; 7:203-220.
12. Cushing SL, Palme CE, Audet N, et al. Prognostic factors in well-differentiated thyroid carcinoma. Laryngoscope 2004; 114:2110-2115.
13. Jukkola A, Bloigu R, Ebeling T, et al. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocrine-related Cancer 2004; 11:571-579.
14. Kushchayeva Y, Duh Q-Y, Kebebew E, Clark OH. Prognostic indications for Hürthle cell cancer. World J Surg 2004; 28:1266-1270. Large series of Hürthle cell carcinomas from one of the most distinguished centers of endocrine surgery in the United States.
15. Machens A, Holzhausen H-J, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 2005; 103:2269-2273. Multivariate analysis of the different prognostic factors of differentiated thyroid carcinoma.
16. Passler C, Scheuba C, Asari R, et al. Importance of tumour size in papillary and follicular thyroid cancer. Br J Surg 2005; 92:184-189.
17. Orsenigo E, Beretta E, Fiacco, et al., Management of papillary microcarcinoma of the thyroid gland. Eur J Surg Oncol 2004; 30:1104-1106.
18. Lin J-D, Chao T-C, Chou S-C, Hsueh C. Papillary thyroid carcinomas with lung metastases. Thyroid 2004; 14:1091-1096.
19. Kouvaraki MA, Lee JE, Shapiro SE, et al. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 2004; 136:1183-1191. Study evaluating the reasons for re-operations for papular thyroid carcinoma.
20. Passler C, Scheuba C, Prager G, et al. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. Endocrine-related Cancer 2004; 11:131-139. Multivariate analysis of risk factors in a large series of patients with differentiated thyroid carcinoma.
21. Goropoulos A, Karamoshos K, Christodoulou A, et al. Value of the cervical compartments in the surgical treatment of papillary thyroid carcinomas. World J Surg 2004; 28:1275-1281.
22. Uruno T, Miyauchi A, Shimizu K, et al. Prognosis after reoperation for local recurrence of papillary thyroid carcinoma. Surg Today 2004; 34:891-895. Systematic neck dissection for re-operative PTC provides better results than 'berry picking'.
23. Thompson GB, Hay ID. Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma. World J Surg 2004; 28:1187-1198. An excellent and comprehensive review on 21 studies on childhood PTC, with comments form an excellent endocrine center.
24. Dralle H, Sekulla C, Haerting J, et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery 2004; 136:1310-1322. Largest study on neuromonitoring of the recurrent laryngeal nerve during surgery.
25. Yarbrough DE, Thompson GB, Kasperbauer JL, et al. Intraoperative electromyographic monitoring of the recurrent laryngeal nerve in reoperative thyroid and parathyroid surgery. Surgery 2004; 136:1107-1115.
26. Hermann M, Hellebart C, Freissmuth M. Neuromonitoring in thyroid surgery: prospective evaluation of intraoperative electrophysiological responses for the prediction of recurrent laryngeal nerve injury. Ann Surg 2004; 240:9-17. Prospective randomized trial on neuromonitoring of the recurrent laryngeal nerve during surgery.
27. Gimm O, Ukkat J, Niederle BE, et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 2004; 28:1312-1316. Results from a multicenter study on MEN 2A-related RET mutations not affecting codon 634, which attempts to define risk groups according to the different mutations.
28. Ukkat J, Gimm O, Brauckhoff M, et al. Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg 2004; 28:1271-1274. Outstanding results in the surgical treatment of medullary thyroid carcinoma. Provides important information on surgical concepts, excellent results and low complication rates, despite a challenging operative technique.
29. Hotz HG, Runkel NS, Frank-Raue K, et al. Prophylactic thyroidectomy in MEN IIA: does the calcitonin level correlated with tumor spread? Langenbecks Arch Surg 1998; 383:170-173.
30. Quayle FJ, Moley JF. Medullary thyroid cacrinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol 2005; 89:122-129. Excellent, concise review on diagnosis, surgical and medical treatment of medullary thyroid carcinoma.
31. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab 2001; 86:5658-5671.
32. Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003; 138:409-416.
33. Machens A, Gimm O, Hinze R, et al. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 2001; 86:1104-1109.
34. Quayle FJ, Benveniste R, DeBenedetti MK, et al. Hereditary medullary thyroid carcinoma in patients greater than 50 years old. Surgery 2004; 136:1116-1121. Important results on a subgroup of patients with MEN.
35. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol 2005; 63:87-93. Comprehensive data on the prognosis of differentiated thyroid carcinoma with distant metastases.